Loading quotes...
Forecast
The analysts' average price target is €346.30 (+8.54%). The median is €349.98 (+9.70%).
| Buy |
26 |
| Hold |
9 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 3.36bn | 10.77% |
| Gross profit | 978.29m | 11.99% |
| Net profit | 232.01m | 4.28% |
| EBITDA | 503.31m | 4.73% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €25.78bn |
Number of shares | 81.1m |
52-week high/low | €331.66 - €218.59 |
| Dividends | No |
Beta | 0.85 |
P/E ratio | 28.98 |
PEG ratio | 1.48 |
P/B ratio | 3.26 |
P/S ratio | 1.98 |
Company profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
| Name | Laboratory Co. of Amer. Hld |
| CEO | Adam H. Schechter |
| Headquarters | Burlington,
nc USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 15/02/2018 |
| Employees | 71,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | LH |
London Stock Exchange | 0JSY.L |
Frankfurt | LAB.F |
Düsseldorf | LAB.DU |
London | 0JSY.L |
SIX | LAB.SW |
München | LAB.MU |